jual kayu murah menerima order bahan
Showing posts with label Basser-PR. Show all posts
Showing posts with label Basser-PR. Show all posts

Basser Center Director quoted in Marketplace

Basser Research Center for BRCA Director Susan Domchek, MD was quoted in a recent Marketplace report on drug shortages. Dan Gorenstein reports on shortages in the supply of drugs for cancer and other conditions, quoting Dr. Domchek who says that this lack of medication puts patients at risk.
photo of Basser Research Center Director, Susan Domchek, MD
“It is a very difficult thing to explain to a patient, why you can’t get a very standard chemotherapy regimen because you don’t have access to the medication,” she says.



Basser External Research Grant Program Receives Additional Funding

Penn Medicine's Basser Research Center for BRCA has announced the Basser External Grant Program, that focuses on projects designed to advance the care of individuals living with BRCA1 and BRCA2 mutations.

Bringing Support to BRCA1/2 Research

The Basser External Grant Program has been made possible thanks to an additional $5 million donation from University of Pennsylvania alumni and Basser Center founders, Mindy and Jon Gray.

“As the nation’s only center solely devoted to research into the prevention and treatment of BRCA-related cancers, the Basser Research Center for BRCA is uniquely positioned to help fund team science and original ideas,” says Dr. Chi Van Dang, director of Penn Medicine’s Abramson Cancer Center.

The grant program provides support for basic science, early detection, translational or clinical research and relevant to the study of BRCA1/2.

“This generous award by the Grays will help expand the mission of the Basser Center by allowing us to support innovative researchers outside of Penn and widen the circle of those who are working to find new ways to prevent and treat cancers associated with BRCA mutations,” says Dr. Susan Domchek, executive director of the Basser Research Center and the Basser Professor of Oncology at the Abramson Cancer Center.

“There are many research teams doing exceptional work in BRCA1/2 research who are finding it difficult to compete for the shrinking pool of federal and foundation funding for biomedical research, and this program provides a new avenue to accelerate progress across the field.”

Recognizing and funding leaders in the field of BRCA research is a cornerstone of the Basser Center’s mission

Last year, the first Basser Global Prize was awarded to cancer biology and genetics expert Alan Ashworth, chief executive officer of the Institute for Cancer Research in London and leader of the Gene Function team in the ICR’s Breakthrough Breast Cancer Research Centre.

As part of the award, Dr. Ashworth, a pioneer in efforts to develop therapies to target cancer cells that contain BRCA1 and BRCA2 mutations, will give the keynote address at the annual Basser Research Center for BRCA Symposium in May 2014.

In 2013, the Basser Center awarded its second year of grant funding—more than $2 million—to 19 Penn investigators representing a wide array of disciplines.

Read the official press release in full here. To learn more
about the Basser Team Science Award and Basser Innovation Award visit Basser.org.

Changes to DNA On-Off Switches Affect Cells’ Ability to Repair Breaks, Respond to Chemotherapy

A Penn Medicine News Release came out today highlighting a finding by Basser Investigator Roger Greenberg, PhD in collaboration with postdoctoral researcher Jiangbo Tang, PhD.

Greenberg and Tang found a key determinant in the balance between two proteins, BRCA1 and 53BP1, that affect cells’ response to chemotherapy.

BRCA and the Arts


What does classical music have to do with hereditary breast and ovarian cancer?

This fall at the Jewish Community Center in Manhattan, the fifth season of PREformances with Allison Charney begins, with funds raised benefiting The Basser Research Center for BRCA of Penn Medicine’s Abramson Cancer Center and programs at the Jewish Community Center in Manhattan that promote early detection of cancer and care for those living with breast and ovarian cancer.

Given that one in forty carrier individuals of Ashkenazi Jewish ancestry carries a mutation in the BRCA1 or BRCA2 genes, the series also plays an important role in educating the community about hereditary forms of breast and ovarian cancer.

PREformances affords celebrated classical musicians the opportunity to try out new concert repertoire in front of understanding audiences prior to performing it in major venues.

Read the Examiner article on PREformances and hear Allison Charney sing here.

The Basser Research Center for BRCA at Penn Focuses on BRCA1 and BRCA2

The Basser Research Center for BRCA supports research on the BRCA1 and BRCA2 genes, harmful forms of which are linked to greatly increased risks of developing breast and ovarian cancer. The Center is named in honor of Mindy Gray’s sister, Faith Basser, who died of ovarian cancer at age 44.

The Basser Research Center for BRCA was established with a $25 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray.

Emphasizing outreach, prevention, early detection, treatment and survivorship, the Basser Research Center for BRCA will contribute to all stages of research and clinical care relevant to BRCA-related cancers.

The breast cancer program at Penn's Abramson Cancer Center helps you understand your options. Learn the facts and request a consultation today.

Bloomberg, Philly.com, 6ABC turn to Basser for BRCA Information

The Basser Center for BRCA Research and executive director Susan Domchek, MD made headlines this week as major news outlets turned to Penn Medicine for an expert opinion. Read the headlines and quotes below:

Bloomberg News quoted Susan Domchek, MD, executive director of the Basser Research Center for BRCA in article on Jolie’s decision:

Jolie Mastectomy Fuels Debate on Breast Cancer Treatment
Those two paths, each with risks and benefits, can leave patients confused and conflicted over how best to protect themselves, said Susan Domchek, a breast cancer researcher and director of the Basser Research Center at the University of Pennsylvania. Jolie said she chose to have a double mastectomy after learning she had the genetic mutation that increased her risk for cancer, which killed her mother. Read more at Bloomberg here.


Domchek was also quoted in a Philadelphia Inquirer piece on Angelina Jolie’s op-ed on carrying a BRCA1mutation and opting for a double mastectomy:

Jolie’s Difficult Medical Decision Wins Praise

"It's not the magic solution," Domchek said. "But it's a compelling example of how, if you know the biology of the cancer, you can use it." Read more at Philly.com here.


6 ABC also quoted the Basser executive director in an article about Jolie’s decision to get preventive mastectomies:

Understanding Angelina Jolie’s Decision

Dr. Susan Domchek of the University of Pennsylvania's Basser Research Center for BRCA, says easy access to information, and a wider range of reconstruction options figure are factors in the rise. Read more at 6 ABC here.




For the latest information on BRCA research, 
screening and clinical trials from 
The Basser Research Center for BRCA,
visit the official webpage.

Basser in the New York Times: Jolie’s Disclosure of Preventive Mastectomy Highlights Dilemma



Susan Domchek, MD, executive director of the Basser Research Center for BRCA is quoted in a New York Times article on Jolie’s decision:

"It is generally considered safe to wait long enough to have children before having the ovaries removed, but the operation should be done by age 40," said Dr. Susan M. Domchek, an expert on cancer genetics at the University of Pennsylvania and the executive director of its Basser Research Center, which specializes in BRCA mutations.

We invite you to read the article in full at the
New York Times here, and for more of the latest information on BRCA research, testing and more

visit the official Basser webpage.

The Angelina Effect (Video)

"The genes that you're born with don't change over the course of your lifetime, however, genetic testing techniques [does]..."

Susan Domchek, MD executive director of the Basser Research Center for BRCA in the Abramson Cancer Center, was interviewed on MSNBC about the news that actress Angelina Jolie carries the harmful BRCA 1 mutation, which led her to undergo a prophylactic mastectomy to reduce her risk of developing breast cancer.



Visit NBCNews.com for breaking news, world news, and news about the economy





For the latest information on BRCA research, 
screening and clinical trials from 
The Basser Research Center for BRCA,
visit the official webpage.

Basser Quoted on Marie Claire and MedCityNews for BRCA Expertise

The Basser Center for BRCA Research's executive director Susan Domchek, MD and Abramson Cancer Center genetic counselor Jacquelyn Powers made headlines this week as major news outlets turned to Penn Medicine for an expert opinion. Read the headlines and quotes below: 

Marie Claire interviewed Domchek for an article about BRCA and Jolie’s decision:

Angelina Jolie: I had a double mastectomy

"We know from our research that having a prophylactic (preventative) mastectomy is the most effective way to for women who carry BRCA1/2 mutations to reduce their risk of developing breast cancer, but that surgery does come with costs, especially around body image, which is understandably an important factor for women," says Domchek "That's why we're working to develop other ways to prevent cancer in these high-risk women — like vaccines and new medications — so that women someday have new, less invasive options." Read more at Marie Claire here.
Jacquelyn Powers was the go-to source for MedCityNews piece on Angelina Jolie’s decision to follow up her BRCA1 screening with a double mastectomy: Is Angelina Jolie’s Surgery a Logical Response to Genetic Test Results?
“I would say what is our gold standard is what’s in the family’s personal history that sets us down a certain path,” said Powers. “Women are more inclined to choose preventive surgery if they have lost someone close to them — that’s a big factor.” Read more at MedcityNews.com here.


For the latest information on BRCA research, 
screening and clinical trials from 
The Basser Research Center for BRCA,
visit the official webpage.

Basser Center Story at Ovarain Cancer Research Fund

The Ovarian Cancer Research Fund provides an interview with Mindy Gray, “Wife, Mother, Sister, Philanthropist, and OCRF Board Member.” Mindy and Jon Gray are the founding donors of the Basser Research for BRCA.

 The ultimate goal of the The Basser Center is eradicating risks from BRCA-related cancers once and for all. The Center is focused on funding scientific research and giving brilliant research scientists the state-of-the-art facilities and the freedom to discover innovative paths to treatment, prevention and cure. With the leadership of Dr. Chi Dang, Director of the Abramson Cancer Center, and Dr. Susan Domchek, Executive Director of the Basser Research Center, we are confident that we can make huge progress towards this goal.


For more information, visit the Basser Research Center for BRCA online.

Would You Shield Your Future Child From Cancer?

Of course we all would, if it were always straight forward. This is the title question of a recent Wall Street Journal Health segment online. Based on WSJ reporter Bonnie Rochman’s article on a family who used reproductive technology to avoid passing on a BRCA mutation to their children, the segment explores the issue of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer caused by mutations in BRCA1 and BRCA2.

BRCA1 and BRCA2 mutations are associated with greatly increased risks for breast and ovarian cancer; as well as moderately increased risk for prostate, melanoma, male breast, and pancreatic cancers.

What is Embryo Screening or Pre-implantation Genetic Diagnosis (PGD)?

Pre-implantation Genetic Diagnosis (PGD) is a special form of in-vitro fertilization (IVF). This can be an option for individuals who carry a known genetic condition and wish to greatly decrease the chances of passing it on to a child. PGD is also known as "embryo screening" and is performed in a laboratory. This procedure is used in combination with IVF to test embryos (fertilized eggs) for a specific genetic mutation, such as a BRCA1 and BRCA2 gene mutation.

The testing is performed before transferring the embryo into the woman's womb. Only the embryos that test negative for the known mutation will be transferred. As the Wall Street Journal highlights, PGD for BRCA1 and BRCA2 and other diseases is a very personal decision and can be seen by many as controversial. Even the couple Rochman initially followed had different perspectives on using the technology.

BRCA Gene Mutation and Reproduction

The Basser Research Center for BRCA is actively researching the impact of BRCA1 and BRCA2 mutations on reproductive attitudes and behaviors. Basser researcher Clarisa R. Gracia, MD, MSCE is investigating the impact of carrying a BRCA mutation on fertility and reproductive decision-making.

“PGD is an option, so we tell patients about it,” says Rebecca Mueller, MS, CGC, CCRC, outreach coordinator for the Basser Center with a strong background in genetic counseling. “But it is a tentative conversation: We broach the topic, explain the option and let the patient take the lead. Some welcome the information and consider it an opportunity to end the pattern of cancer risk within their family. Others say that they or their kids may not be here had the testing been available and the conversation may end there.”

The Basser Research Center for BRCA aims to educate individuals who carry BRCA mutations about their options across the board. “Whether we are talking about genetic testing, cancer screening, prophylactic measures, treatment choices, or reproductive decisions, it is our goal to provide information and support to families facing BRCA” says Basser Center Director, Susan Domchek, MD.

Watch the Wall Street Journal piece online, 
and visit Basser.org for the latest in BRCA news, education and research.

Direct to Consumer Genetic Testing: What’s all the Fuss?

A mother testing her adopted child’s genome...

A young woman learning from a spit-and-send test that she is at markedly increased risk for breast and ovarian cancer...

A reporter who sends samples to multiple direct-to-consumer genomics companies, each with unique and variable results...

These are just a few of the stories to surface around the recent warning letter sent by the US Food and Drug Administration to a Direct-to-Consumer (DTC) genomics testing company.

The warning letter stated that the company had not provided adequate evidence that the Personal Genome Service provides accurate assessment of disease risk. This news and related stories have popularized discussions that have been taking place within the walls of genetic medicine for quite some time.

“The variability of results from DTC testing is not exactly a new finding,” says Susan Domchek, MD, executive director of Penn Medicine’s Basser Research Center for BRCA. “Starting around 2010, researchers have illustrated similar discrepancies by sending batches of samples to DTC companies and publishing the results. It is widely understood that each lab looks for slightly different genetic markers and may interpret the same data differently.”

What is direct-to-consumer genetic testing? What do the tests look for? What are the risks and benefits to this type of testing?

Basser Center genetic counselor Rebecca Mueller MS, CGC, CCRC explains.

Q: What is direct-to-consumer genetic testing?

Direct-to-consumer- or DTC- genetic testing is genetic testing that is arranged directly between a consumer and a company with no medical professional intermediary. Most of the companies provide saliva sample kits that are mailed in for genetic testing at a company laboratory.

Q: What conditions do DTC tests look for?

DTC tests have been marketed to test for everything from ancestry, to carrier status for recessive conditions, to disease risk, to paternity. Currently, the FDA is concerned about DTC testing for disease risk. These genetic tests for disease risk typically look at what we call SNPs or Single Nucleotide Polymorphisms.

Q: What exactly are Single Nucleotide Polymorphisms (SNPs)?

These are small differences in the genome at specific places in the genetic code that are commonly found in people. Through studies of large samples of individuals, scientists have identified many, many SNPs that increase or decrease risk for different diseases within certain populations.

Q: Why do reported disease risks vary depending on the company doing testing?

Many things contribute to disease risk—not just genetics.  While we know that genetic variation contributes to disease risk, there are several reasons why results vary by laboratory.

First, many SNPs typically contribute to risk of any given disease and different laboratories may look at different SNPs.

Second, even if two laboratories are looking at the same SNP they may interpret results differently for a variety of reasons. For example, they may have different data about the baseline or average risk for a given disease in a particular population, and the increase or decrease in risk is based off of that data.

Regardless of what the genetic reports say, there are a few more things to consider: We have yet to define all the genetic variations that contribute to disease risks, so every test has important limitations. We also know that there are many non-genetic factors that affect disease risks significantly, so even a hypothetically perfect genetic test would have limitations. For example, you can lack genetic risk factors for obesity but still be obese.

Q: Are DTC companies doing BRCA testing?

It is important to understand that most DTC companies do not comprehensively sequence genes, meaning they cannot rule out the presence of a mutation with the same precision as the laboratories used in medical settings. For example, one company tested people’s samples for three specific mutations within the BRCA1 and BRCA2 genes that are commonly found in the Ashkenazi Jewish population, but the company did not provide comprehensive genetic testing (also called full sequencing) of the BRCA genes. Individuals might think they had negative BRCA1/2 testing, when in fact they had very limited testing that is insufficient for ruling out a BRCA mutation.

Q: Are SNP test results medically useful?

Many things contribute to risk for any given disease. Currently, family history and personal medical history and exposures are the best way to assess risk for many types of cancer. In some individuals, genetic testing of certain genes (not SNPs, but entire genes such as BRCA1 and BRCA2 and genes for hereditary colon cancer) can be very useful. These tests can be ordered by medical providers when indicated to shed more light on inherited cancer risk. Comprehensive testing of these genes is not available through DTC companies.

Interested in learning more? 
Genetic counselors at the Marian and Robert MacDonald Women’s Cancer Risk Evaluation Program and the Division of Translational Medicine and Human Genetics provide risk assessment and genetic testing for a variety of conditions.

Penn's Basser Research Center for BRCA Names UK Breast Cancer Researcher Alan Ashworth Winner of First Annual Basser Global Prize

The Basser Research Center for BRCA has announced the recipient of its first annual Basser Global Prize. The honor will go to cancer biology and genetics expert Alan Ashworth, FRS, Chief Executive Officer of the Institute for Cancer Research in London and leader of the Gene Function team in the ICR’s Breakthrough Breast Cancer Research Centre.

The Basser Global Prize, a marquee component of the Basser Research Center for BRCA, was established by Shari Basser Potter and Leonard Potter to honor a visionary scientist who has conceptually advanced BRCA1 and BRCA2 related research that has led to improvements in clinical care.

Professor Ashworth’s laboratory focuses on using genetic principles to understand cancer biology and channel the findings into information to change the way patients are treated. His lab has been instrumental in the development of PARP inhibitor therapy, medications that are designed to target the genetic vulnerability of BRCA1- and BRCA2-related cancers.

Eye Witness News 3 in Connecticut reports on family's Basser Research Center experience

Eye Witness News 3 in Connecticut reports on Kate Berges’ families experience with BRCA, noting Berges attendance at the Philadelphia opening of Basser Research Center for BRCA.


For the latest information on BRCA research, screening and clinical trials from The Basser Research Center for BRCA,visit the official webpage.

Learn About the Basser Research Center Through ShareWik

Have you heard of the Basser Research Center?

Until recently, neither had Jan. Even as a seven-year cancer survivor, she continues to learn about the available resources.

Jan Jaben-Eilon discusses how a friend introduced her to Penn Medicine’s Basser Research Center for BRCA over lunch. She encourages you, too, to get acquainted with the Basser Center.

Read her post on ShareWik, a website aimed at using the power of personal storytelling to engage, educate and inspire others about decisions that impact their health.

Read Jan's blog here.

Accentuate the Positive: Eva Moon at the Joining FORCEs Conference

More than 700 individuals facing hereditary breast and ovarian cancer gathered at the Philadelphia Marriott for the 2014 Joining FORCEs Conference held by Facing Our Risk of Cancer Empowered in partnership with Penn Medicine’s Basser Research Center for BRCA.

As the Philadelphia Inquirer reports, performer Eva Moon spoke at the 2014 joining FORCEs Conference last month, integrating humor with the otherwise serious topic of hereditary cancer.

Hereditary breast and ovarian cancer is often caused by mutations in the BRCA1 and BRCA2 genes, which increase risk for breast, ovarian and other cancers.

Moon, who carries a BRCA1 mutation, uses humor as a method to cope with tough times. She performs a one-woman musical about her journey with hereditary breast and ovarian cancer.

At the conference, Moon shared her personal story, tips for finding humor in daily life, and engaged the audience with a number of songs and activities.

"I cried rivers of tears," she said. But she fought back and underwent a series of major preventative surgeries. Post-recovery, Moon harnesses humor for coping with hard times, and she is teaching others to do the same.

"Humor can relieve stress and speed healing," she said.


BRCA Beat: 2014 Winter Issue

Herbert and Betty Adelman, supporters of the Basser Research Center for BRCA
Happy New Year from the Basser Research Center for BRCA.

Basser's quarterly e-newsletter reports on donors Herbert and Betty Adelman, the latest in BRCA research, the announcement of the Basser External Research Grant, upcoming BRCA educational events, and other important center updates:

Herbert and Betty Adelman live in Virginia and first read about the Basser Research Center for BRCA in the New York Times. A 1952 graduate of the Wharton School and part of a family personally affected by the BRCA gene, Herbert and his wife Betty decided to come to Penn to learn more about the Center’s vision and research goals...


Read the whole Winter 2014 edition here:
BRCA beat eNewsletter

BRCA Beat: Spring Issue


Read the most recent edition of the Basser Center for BRCA Reseach’s quarterly e-newsletter. 

This newsletter reports on donor Andy Cohen, provides an update on current BRCA related clinical research and promotes upcoming Basser events! 






Read the full newsletter coverage and sign up for the future editions here.

New York Times article on Universal Screening for BRCA1/2 cites the Basser Research Center’s Jewish Outreach Campaign

Jewish Ashkenazi Outreach Program buttonJewish Ashkenazi Outreach Program buttonJewish Ashkenazi Outreach Program buttonJewish Ashkenazi Outreach Program Jewish Ashkenazi Outreach Program buttonBRCA mutations are much more common in individuals of Ashkenazi Jewish ancestry, making population screening worth consideration.

New York Times correspondent Roni Caryn Rabin reports on the issues associated with universal screening for BRCA mutations in Israel, noting the Basser Research Center for BRCA’s efforts to raise awareness of BRCA1/2 via a poster campaign in American synagogues.

The Basser Research Center for BRCA at Penn Focuses on BRCA1 and BRCA2

The Basser Research Center for BRCA supports research on the BRCA1 and BRCA2 genes, harmful forms of which are linked to greatly increased risks of developing breast and ovarian cancer. The Center is named in honor of Mindy Gray’s sister, Faith Basser, who died of ovarian cancer at age 44.

The Basser Research Center for BRCA was established with a $25 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray.

Emphasizing outreach, prevention, early detection, treatment and survivorship, the Basser Research Center for BRCA will contribute to all stages of research and clinical care relevant to BRCA-related cancers.

"I Feel Like I've Beat Cancer." - Carlette, Breast Cancer Survivor

Growing up, cancer was a common topic in Carlette Knox’s household.

One of five daughters, Carlette’s mother was a two-time breast cancer survivor who eventually lost her fight with pancreatic cancer in 2011. Her father died of colon cancer, and many members of her family fought cancer in some form.

Yet when Carlette felt a lump in her breast in fall of 2009 at the young age of 34, she blew it off hoping it would go away on its own.

“At the time, my mother was going through treatment for pancreatic cancer, and I had a lot going on in my life,” she remembers. “Plus, I had already had a mammogram just a few months before, so I didn’t think it could be cancer.”

Six weeks later in December, when the lump hadn’t gone away, Carlette made an appointment for another mammogram that confirmed what she’d known deep down inside – she had breast cancer.

What Carlette didn’t know at the time, however, was that she was BRCA positive. Carlette carried a mutation on the breast cancer gene that made her predisposed to developing breast and ovarian cancer.

“My mother was diagnosed at the age of 35 and she experienced the devastating loss of her mother to this disease while growing up,” says Carlette who underwent BRCA mutation testing in 2010. “I also witnessed two of my aunts lose their battles with cancer. I knew firsthand the impact this disease had on the women in my family; the need to attack this diagnosis head on was evident.”

“I was introduced to the risk assessment program and with the help of a genetic counselor underwent testing to determine my cancer risks,” remembers Carlette. “When I learned I had a genetic mutation, I felt targeted. I don’t know why, I just took that diagnosis very personally – more so than my breast cancer diagnosis.”

However, that knowledge helped Carlette make the decision to have a bilateral mastectomy, complete removal and reconstruction of her breasts, as well as an oophorectomy, removal of her ovaries to reduce her risk of breast and ovarian cancer. Carlette also underwent chemotherapy to treat the breast cancer she had already developed.

“Learning about BRCA put into perspective my risk of breast cancer recurrence and ovarian cancer. My decision to remove the non-impacted breast tissue was supported by clinical trial data as well as my personal experience," she says.

"Seeing the effects of this disease throughout generations of women in my family was not a tradition I was willing to keep. While the procedure to have my ovaries removed itself was minimally invasive, the decision was not without much emotional turmoil on the inside. In my mind, this would change my landscape as a woman at such a young age. Ultimately, after researching the effects of ovarian cancer, I embraced this option as a blessing not a curse."

Today, Carlette is physically and emotionally better than she could have ever imagined.

“I don’t look or feel like any of what I went through. It may sound a bit crazy, but I’m grateful for the journey. My faith is stronger and as a result of this life changing experience I’ve been able to embark upon yet another journey.”

Carlette has become an advocate for women with breast cancer and the BRCA mutation at “Life Worth Living.”

“Life Worth Living is the realization of my passion to raise awareness, empower and support those impacted by cancer and to broadcast the message of hope aspiring them to live,” says Carlette.

“Today, I feel like I have beat cancer. I did everything I could do from a care standpoint, and I want to give as much as I can, because I keep seeing younger women impacted by a breast cancer diagnosis. I want help women find their voice and tap into the hope of overcoming their diagnoses and treatments.”


Penn Medicine's Abramson Cancer Center is leading the way in breakthrough cancer treatment. If you or someone you know has been touched by cancer, the power to find the Cure is Within.
Hear our stories and find out more today.

What If...



Jane E. Herman, a BRCA2 mutation carrier, is the executive writer and editor at the Union for Reform Judaism. She also volunteers as an Outreach Coordinator for the New York City chapter of FORCE: Facing our Risk of Cancer Empowered and blogs regularly about her BRCA journey and other slices of her life at JanetheWriter Writes…

Two weeks ago, in the midst of staffing the Union for Reform Judaism’s Biennial Convention in San Diego, I ran into a friend of my mom’s. She introduced me to the woman she was with as “Diana’s daughter.” Proud to wear the title, I was sad, too, that a BRCA mutation she didn’t even know she carried had cut short my mom’s life. Yet again, she was missing a Biennial gathering and one of the things she loved most about them—connecting and reconnecting with so many friends and clergy in her beloved Reform Jewish family.

The next day, I got to do something about that.

No, of course I can’t bring my mom back, but I was honored to speak—together with Susan Domchek, MD and Rabbi Marci Zimmerman—in a BRCA awareness session entitled “Hereditary Cancer and the Jewish Community: Knowing Saves Lives.” The session was the outgrowth of last fall’s high holiday BRCA awareness campaign sponsored by the Basser Research Center for BRCA that originally was the brainchild of Ellen Perl, a congregant of Rabbi Zimmerman’s and a breast cancer survivor.

Following opening remarks and a brief introduction of the panelists, Dr. Domchek provided a science-based overview of BRCA mutations, which are 10 times more prevalent among Ashkenazi Jews than they are within the general population. In addition to breast and ovarian cancer, she discussed other cancers associated with these genetic flaws, as well as the mutations’ autosomal dominant pattern of inheritance, which means that if just one parent is a mutation carrier, each child has a 50% chance of inheriting it from that parent. Short videos, detailing a few real women’s BRCA stories rounded out her presentation.

Rabbi Zimmerman then spoke about the important role synagogues can and must play in raising awareness about BRCA mutations within the Jewish community, as well as the critical role of clergy and members in supporting other members and families who carry BRCA mutations, especially as they confront the physical and emotional challenges that can come with them.

Then it was my turn.

My BRCA Story


Ditching my prepared notes, I spoke from my heart, telling the group that my sister and I only learned the details about BRCA mutations because our mother died. Shortly after her death from exceedingly virulent triple negative breast cancer, with sparse knowledge of BRCA mutations on the periphery of our radar, we opted to pursue genetic counseling and testing—not only because she’d died from breast cancer, but also because her sister had previously been diagnosed with the disease many years earlier. (Thankfully, with a mastectomy and chemotherapy, our aunt is a sprightly 86 today!) Although my sister tested negative for a BRCA gene mutation, my results were positive for one of the three Jewish founder mutations carried by one in every 40 Ashkenazi Jews. (When she finally was tested last winter, our aunt, too, turned up positive. Her two grown sons—fathers to three young teens between them—have yet to be tested.)

What if, I wondered out loud, my mom had attended a Biennial session like this one six or eight or even 10 years ago? Would she have connected all the dots in our family, beginning with her father’s prostate cancer in the mid-1980s, a decade before the BRCA genes even were identified? Would her sister’s breast cancer—like her own, diagnosed relatively late in life—have raised a red flag? Would BRCA awareness have changed the trajectory of her life or others’ in our family, including mine?

What if, I wondered to myself — afraid even to formulate the thoughts in my head—we hadn’t been so lucky? Although my oncologist believes there may be some genetic factor protecting the BRCA-positive women in our family from early onset breast cancer, what if that factor, whatever it may be, wasn’t there? With virtually no indication that a mutation was lurking in our family’s genes, we might have lost our mother decades earlier, cheating her and us out of a whole lot of life and love. No less scary, I might have been forced to relinquish my previvor status to a non-prophylactic mastectomy or oophorectomy, radiation, chemotherapy or worse…

In my family, we can’t begin to answer these “What if’s.” But now, with my own risks well under control, these unanswered questions compel me to write blog posts such as this one and to tell and retell my story often. It is my hope that this work of my heart will bring much needed awareness to other families whose members may, unbeknownst to them, be harboring BRCA gene mutations. It is my hope, too, that this information will reach them long before a mother, a wife or a sister dies and the survivors are obliged to confront the painful “what ifs.”

About BRCA and Ashkenazi Jews


Even though the majority of Ashkenazi Jews are not BRCA mutation carriers and only five to 10% of all breast and ovarian cancers are caused by these mutations, it is important to know the possible signs of these hereditary cancers. These include a family member with:
  • Ovarian or fallopian tube cancer at any age
  • Breast cancer before age 50
  • Breast cancer in both breasts at any age
  • Both breast and ovarian cancer
  • Triple negative breast cancer
  • Male breast cancer

Other signs of HBOC syndrome include more than one relative on the same side of the family with any of these cancers:
  • Breast cancer
  • Ovarian or fallopian tube cancer
  • Prostate cancer
  • Pancreatic cancer

If you suspect that you or a family member may be affected by hereditary cancer caused by a BRCA mutation, you may wish to contact a genetic counselor, who is specially trained to assess individuals’ personal cancer risks and help determine appropriate risk management strategies. The National Society of Genetic Counselors can help you find genetic professionals in your area.